Bli medlem
Bli medlem

Du är här


Gabather: Presents at the European Smallcap Event in Paris

Gabather will present the development of its drug development programs (CNS)
at the European Smallcap Event in Paris Aril 11-12. The event is primarily
directed towards accredited and institutional investors.

Gabather has a comparably large number of shareholders which results in a good
liquidity in daily trading of the stock, GABA (Aktietorget, SE). The company
is aiming to attract international institutional investors to strengthen the
support for its long term drug development efforts in the field of Central
Nervous System (CNS) based diseases. Gabather is presenting to investors on
Monday April 11th and will have several one to one meetings on Tuesday.

Gabather CEO Bert Junno comments: "Gabather wishes to attract new
international institutional and private shareholders. The European Smallcap
Event is a very good event to present and meet new prospective owners.."

Gabather AB
Bert Junno, CEO

Gabather AB

Gabather was founded in 2014 as a result of more than ten years of
collaborative research between Lund University (Sweden) and the Research
Institute of Biological Chemistry in Roskilde (Denmark). The aim of the
company is to develop novel small molecule drugs to treat diseases with an
origin in the central nervous system. Gabather founders are the Forskarpatent
fund together with scientists Olov Sterner and Mogens Nielsen..


This press release contains forward looking information including subjective
statements that are prognoses of future developments. The forward looking
statements are only valid on the date they are made and are like research and
development of biotechnical products, high risk activities. With this in mind
acual outcome may differ considerably from what is described in this press


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Gabather AB via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.